After years of denying the obvious, a leading British doctors’ group has moved to accept the Cass Review’s core finding: there is no reliable evidence base for medicating minors into gender transition.
Story Snapshot
- Cass Review concludes evidence for puberty blockers and cross-sex hormones in minors is weak and unreliable [3].
- NHS England halted routine puberty blockers for under-18s in 2024 due to insufficient safety and effectiveness data [4].
- Regulators still approved new trials and the NHS funded a major study, signaling an unsettled debate [4][1].
- Clinicians cannot predict which children will persist in trans identity; medical pathways may not suit most youth [3].
Cass Review’s Core Finding: Evidence Too Weak for Confident Care Decisions
Dr. Hilary Cass’s final report to NHS England concluded that systematic evidence reviews found poor-quality studies underlying pediatric gender treatments, leaving “not a reliable evidence base” to guide clinical decisions for minors [3]. The review states clinicians cannot determine with certainty which children will maintain a trans identity over time and warns that, for the majority, a medical pathway may not be the best approach to address gender-related distress [3]. The finding challenges a decade of activist-driven medical orthodoxy across Western systems.
NHS England responded in March 2024 by ending routine prescriptions of puberty blockers for new patients under 18, citing insufficient evidence on safety and effectiveness as assessed by NICE and reflected in Cass’s interim advice [4]. The decisive policy shift followed years of rising referrals and public concern about the speed and irreversibility of medicalization for adolescents. The move placed the UK among a growing group of European health agencies tightening pediatric gender medicine while prioritizing careful, evidence-based practice [3][4].
Court Caution And Clinical Uncertainty Undercut Activist Narratives
Legal scrutiny intensified caution. In December 2020, the High Court ruled that children under 16 were unlikely to be capable of giving informed consent to puberty blockers, a decision that spurred more restrained prescribing even before NHS England’s 2024 policy turn [4]. Cass further underscored clinicians’ limited ability to predict persistence or desistance, highlighting the risk of exposing vulnerable teens to powerful drugs when long-term outcomes remain uncertain and heterogeneous across patient subgroups [3][4].
Medical record data show low absolute prevalence of recorded transgender identity in UK primary care—about 0.03% in one large analysis—while survey-based estimates run higher, underscoring measurement gaps and policy complexity [2]. Cass acknowledged a complex interplay of biological, psychological, and social factors without a single causal driver for rising referrals, making blanket, protocolized medicalization hard to justify absent robust longitudinal evidence and well-specified patient selection criteria [3][2].
New Trials And Funding Keep The Debate Open, But Do Not Rebuild Confidence Yet
Even as routine prescribing paused, regulators approved the first post-ban clinical trials of puberty blockers in children referred to gender services, involving up to 220 participants, to address key evidence gaps [4]. The NHS also committed roughly $13.9 million to a major study on puberty blockers in gender-distressed minors, signaling an institutional push to generate higher-quality data rather than an endorsement of current practices [1]. These steps reflect scientific due diligence, not a repudiation of Cass’s critique of the present evidence base.
The Big U-Turn — British Doctors' Group Now Accepts Key Study on Transgender Care for Minors https://t.co/CqU0FugyaE
— Rosehead (@Rosehea92496012) May 7, 2026
Critics argue observational studies show short-term benefits and acceptable safety, but Cass’s standard remains anchored in long-term, decision-grade evidence for lifelong interventions in developing bodies [3]. Until trials report durable outcomes, the balance of risk and benefit remains unclear. For families, this means returning first to thorough psychological assessment and support, and for policymakers, it means resisting ideological pressure while data catch up—a stance aligned with protecting children and upholding responsible medicine.
Sources:
[1] The UK Will Spend $13.9 Million On a Puberty Blocker Study—But to …
[2] Transgender identity in young people and adults recorded in UK …
[4]
